Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Y-mAbs announces publication of Phase 2 interim results on naxitamab
Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with ...
Medscape8d
Clinical Applications of Colony-Stimulating Factors: A Historical Perspective
a FDA = Food and Drug Administration, G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte-macrophage colony-stimulating factor, CHO = Chinese hamster ovary, NA = not available.
Le Lézard5d
Savara Announces U.S. Launch of the aPAP ClearPathtm Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an ...
Medscape16d
Colony-Stimulating Factors: Beyond the Effects on Hematopoiesis
with levels increasing after discontinuing sargramostim a GM-CSF = granulocyte-macrophage colony-stimulating factor; BCG = bacillus Calmette-Guérin vaccine; RR = response rate, including complete ...
Cure Today26d
High Omega-3 Diet With Fish Oil Reduces Ki-67 Index in Prostate Cancer
The intervention group showed reduced triglyceride levels and macrophage colony-stimulating factor, with no change in tumor volume or PSA. Further studies, including phase 3 and longer-term trials, ...
PharmiWeb14d
Radiation-Induced Myelosuppression Treatment Market to Reach USD 3.5 Billion by 2028 with a 3.1% of CAGR
Radiation-Induced Myelosuppression Treatment MarketThe global Radiation-Induced Myelosuppression Treatment Market is ...
Finanznachrichten8d
Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory ...
Healio11d
Dietary changes may slow prostate cancer growth during active surveillance
A dietary change that included a decrease in dietary omega-6 and an increase in omega-3 fatty acids could reduce prostate ...
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...
Wedbush Research Analysts Cut Earnings Estimates for YMAB
Investment analysts at Wedbush lowered their Q1 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Wedbush ...